Literature DB >> 13678860

Virus-like particles as immunogens.

Rob Noad1, Polly Roy.   

Abstract

Subunit vaccines based on recombinant proteins can suffer from poor immunogenicity owing to incorrect folding of the target protein or poor presentation to the immune system. Virus-like particles (VLPs) represent a specific class of subunit vaccine that mimic the structure of authentic virus particles. They are recognized readily by the immune system and present viral antigens in a more authentic conformation than other subunit vaccines. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as vaccines, and discuss the characteristics and problems associated with producing VLPs for different viruses.

Mesh:

Substances:

Year:  2003        PMID: 13678860     DOI: 10.1016/s0966-842x(03)00208-7

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  171 in total

Review 1.  Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.

Authors:  Gavin C Bowick; Alexander J McAuley
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  The glycoprotein cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with ribonucleoproteins and is critical for genome packaging.

Authors:  Anna K Overby; Ralf F Pettersson; Etienne P A Neve
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Protein transfer into human cells by VSV-G-induced nanovesicles.

Authors:  Philippe-Emmanuel Mangeot; Sandra Dollet; Mathilde Girard; Claire Ciancia; Stéphane Joly; Marc Peschanski; Vincent Lotteau
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

Review 6.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

7.  Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Sarah A Kenward; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

8.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 9.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

10.  Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.

Authors:  Naoko Uno; Ted M Ross
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.